Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
ZYNLONTA
product3 mentionslast seen Nov 4, 2026
CD19-directed antibody drug conjugate approved for treatment of relapsed or refractory diffuse large B-cell lymphoma.
Relationships 13
- U.S. Food and Drug AdministrationapprovesZYNLONTA99% confidence3 sources
- ADC Therapeutics SAdevelopsZYNLONTA99% confidence3 sources
- ZYNLONTAapplies todiffuse large B-cell lymphoma treatment99% confidence2 sources
- European Medicines AgencyapprovesZYNLONTA99% confidence2 sources
- European CommissionapprovesZYNLONTA96% confidence1 source
- ZYNLONTAapplies torelapsed or refractory diffuse large B-cell lymphoma treatment93% confidence1 source
- ADC Therapeutics SAcommercializesZYNLONTA90% confidence1 source
- ZYNLONTAapplies tomarginal zone lymphoma treatment90% confidence1 source
- ZYNLONTAdepends onantibody-drug conjugate90% confidence1 source
- ZYNLONTAapplies tomantle cell lymphoma treatment85% confidence1 source
- ZYNLONTAapplies tofollicular lymphoma treatment85% confidence1 source
- ZYNLONTAapplies toWaldenström macroglobulinemia treatment85% confidence1 source
- Nippon ShinyakucommercializesZYNLONTA85% confidence1 source
Relationship
European Medicines AgencyapprovesZYNLONTA
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 4, 2026ADC Therapeutics SA 8-K: Item 2.02: Results of Operations and Financial Condition; Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA
- filingSEC EDGAROct 13, 2026ADC Therapeutics SA 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.02: Results of Operations and Financial Condition; Item 3.02: Unregistered Sales of Equity Securities; Item 9.01: Financial Statements and Exhibits
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl)